For development of the breakthrough MultiPath platform and culture-free, anti-microbial susceptibility tests

Hema Diagnostic Systems (HDS) announces the final validation process of a new Anthrax Toxin rapid test for the detection and differentiation between the Anthrax Protective Antigen (PA) and the Lethal Factor (LF) using whole blood or serum.

HEMA DIAGNOSTIC SYSTEMS announces the execution of a non-binding letter of intent with Generex Biotechnology Corporation. HDS and Generex will work together to bring technologies developed by both companies together by incorporating the new and novel rapid diagnostic test systems for worldwide market expansion.

Detection & Identification of Pathogens, Biological Threats and Infectious Diseases -
Detection Technologies is an internationally recognized event for experts in detection and identification of pathogens, biological threats and infectious diseases